Rep. Thomas H. Kean, Jr. Sells Off Shares of Stryker Corporation (NYSE:SYK)

Key Points

• Representative Thomas H. Kean, Jr. sold shares of Stryker Corporation valued between $15,001 and $50,000 on June 26th, 2025.
• Stryker's stock recently traded up 0.8% to $399.86, with a market capitalization of $152.62 billion.
• The company reported earnings of $2.84 EPS for the last quarter, surpassing analyst expectations and achieving a revenue of $5.87 billion.
• Stryker declared a quarterly dividend of $0.84 per share, set to be paid on July 31st, 2025.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on July 16th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on June 26th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.
• Purchased $1,001 - $15,000 in shares of Danaher NYSE: DHR on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of AON NYSE: AON on 5/27/2025.
• Purchased $1,001 - $15,000 in shares of Becton, Dickinson and Company NYSE: BDX on 5/13/2025.
• Sold $1,001 - $15,000 in shares of Crown NYSE: CCK on 5/8/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 5/8/2025.
• Purchased $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 5/5/2025.
• Sold $1,001 - $15,000 in shares of Franklin Resources NYSE: BEN on 4/28/2025.
• Purchased $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 4/24/2025.

Stryker Stock Performance

NYSE:SYK traded down $3.10 during midday trading on Monday, hitting $400.43. The company's stock had a trading volume of 888,445 shares, compared to its average volume of 1,442,338. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. The firm has a market cap of $152.84 billion, a P/E ratio of 54.11, a P/E/G ratio of 2.99 and a beta of 0.91. The firm's 50 day moving average is $386.37 and its 200-day moving average is $379.44.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.50 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.84%. Stryker's payout ratio is presently 45.41%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SYK shares. Roth Mkm raised their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Evercore ISI boosted their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Truist Financial raised their target price on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. Finally, JMP Securities restated a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $428.55.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Capital A Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at $26,000. Sachetta LLC increased its stake in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Stryker during the first quarter worth approximately $32,000. City Holding Co. lifted its position in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after buying an additional 74 shares during the last quarter. Finally, VSM Wealth Advisory LLC acquired a new position in shares of Stryker in the 4th quarter valued at $36,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.90% of the stock is currently owned by company insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.